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498 Reoperations after tricuspid valve repair
José M. Bernal, MD, Dieter Morales, MD, Carmen Revuelta, MD, Javier Llorca, MD,
Jesús Gutiérrez-Morlote, MD, and José M. Revuelta, MD, Santander, Spain
Seventy four patients underwent tricuspid valve reoperation for previous tricuspid valve repair
dysfunction with a high early (35.1%) and late mortality (40.5%). The actuarial survival curve
was 11.8%  4.9% at 26 years.
504 Different patterns of extracellular matrix protein expression in the convexity
and the concavity of the dilated aorta with bicuspid aortic valve:
Preliminary results
Maurizio Cotrufo, MD, Alessandro Della Corte, MD, Luca S. De Santo, MD,
Cesare Quarto, MD, Marisa De Feo, MD, Gianpaolo Romano, MD, Cristiano Amarelli, MD,
Michelangelo Scardone, MD, Franca Di Meglio, MD, Germano Guerra, MD,
Maria Scarano, MD, Serena Vitale, MD, Clotilde Castaldo, MD, and
Stefania Montagnani, MD, Naples, Italy
In patients with a bicuspid aortic valve, fibronectin and tenascin (known to increase in flow-
induced vascular remodeling) were overexpressed in the right anterolateral wall of the dilated
aorta, whereas type I and III collagen were reduced. Significant differences were found in
collagen amount and synthesis between patients with regurgitation and with stenosis.
512 One-year outcomes of coronary artery bypass graft surgery versus
percutaneous coronary intervention with multiple stenting for multisystem
disease: A meta-analysis of individual patient data from randomized clinical
trials
Nestor Mercado, MD, PhD, William Wijns, MD, PhD, Patrick W. Serruys, MD, PhD,
Ulrich Sigwart, MD, Marcus D. Flather, MBBS, Rodney H. Stables, DM, FRCP,
William W. O’Neill, MD, Alfredo Rodriguez, MD, Pedro A. Lemos, MD, PhD,
Whady A. Hueb, MD, Bernard J. Gersh, MB, ChB, DPhil, Jean Booth, MSc, and
Eric Boersma, PhD, Rotterdam, The Netherlands; Aalst, Belgium; Geneva, Switzerland; London
and Liverpool, United Kingdom; Royal Oak, Mich; Buenos Aires, Argentina; São Paulo,
Brazil; and Rochester, Minn
One year after the initial procedure, PCI with multiple stenting and CABG surgery provided a
similar degree of protection against death, MI, or stroke for patients with multisystem disease.
Repeat revascularization procedures remain higher in PCI with multiple stenting compared with
CABG surgery, but the difference has narrowed in the era of stenting.
520 Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation
of the 3F aortic bioprosthesis
James L. Cox, MD, Niv Ad, MD, Keith Myers, BS, Mortiz Gharib, PhD, and
R. C. Quijano, MD, PhD, St Louis, Mo, Jerusalem, Israel, and Pasadena, Calif
A new tubular aortic bioprosthesis was compared in vitro with a commercially available
stentless bioprosthesis. The tubular valve showed lower gradients, greater effective orifice areas,
superior flow hemodynamics, more optimal stress distribution, and better long-term durability
than the control valve for all sizes and under all test conditions.
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